SUPPORT FOR
YOUR PATIENTS
AND PRACTICE

Everything you’d expect from the
#1 prescribed HA1

Solution Center

A hub that streamlines
everything from coverage
verification to patient support

Let us help you navigate the
coverage landscape*†

Our denial rate is <1%

Benefits Investigation (BI)
doesn't have to be a burden*†

BIs completed in 24 hours with
online progress tracking

More than 600,000+ completed
BIs over 10 years2

We connect patients to support

Comprehensive programs such as
HAppy Knees and Patient Direct

EUFLEXXA Solution
Center Guide

Download
For Solution Center questions call 1-866-383-5391 or Fax 1-866-383-5392

*The Solution Center will respond to each fax submission within
24 hours, notifying you of a patient’s coverage
via the Benefits
Investigations Report.

The EUFLEXXA Solution Center does not file claims or
appeal-claims, and cannot guarantee that you will be
successful
in obtaining reimbursement. Third-party payment for medical
products and services is affected by
numerous factors, none of
which can be anticipated or resolved by the Solution Center.

The percentage of cases where the insurance company has
not made payment after benefits are verified and
claims have
been submitted.

HA=hyaluronic acid.

Access

Most insured patients
have access
under their
medical benefits2

Preferred formulary status by many of the
largest
commercial plans, with fewer
access restrictions*

EUFLEXXA is covered under the pharmacy benefit
by many insurers such as United
Healthcare,
OptumRx, Express Scripts, and the Veterans
Administration.

100% coverage on Medicare Part B without restriction

*Subject to change based on individual plan coverage. Check the
member’s benefits for more details.

Preferred access refers to favorable formulatry status, medical
policy, or fewer restrictions for EUFLEXXA.

Allowed for buy and bill.

§BCBS IL, BCBS MT, BCBS NM, BCBS OK, and BCBS TX.

HA=hyaluronic acid.

Copay Relief Program

How Patients Redeem their Copay Relief:*

  1. Patients visit euflexxa.com/copayrelief to download and print out their copay relief form.
  2. After patient has filled out the form, their healthcare provider must fill out and sign remaining portion.
  3. Patient may mail, fax, or electronically submit through patient portal along with explanation of benefits or itemized receipt inclusive of patient portion paid to health care provider and copy of patient's insurance card (front and back).
  4. Patients will receive their copay relief rebate in 10 -14 business days.

*See eligibility criteria

Patients can help us support healthcare workers by donating

$5 to Direct Relief. Ferring will match each donation.

Eligibility

Patient Direct

A direct-purchase
alternative for underinsured
and uninsured patients*

Available to a wide range of patients

Patients who may participate include those with
high deductibles, patients with insurance plans
with limited coverage, and the uninsured*

Quick and easy to enroll

Enroll your patients via fax or online through the
Solution Center. Your patients will receive a text
or email
to authorize their participation

CareMed manages the details so you
can treat within days

CareMed Specialty Pharmacy will contact the
patient by
phone to confirm the prescription and
collect payment.
EUFLEXXA is shipped to your
office in 3 to 5 business days

The flexibility you need to help your patients get the treatment they need

*See eligibility criteria.

HA=hyauronic acid.

Patient Assistance

Help eligible patients
get EUFLEXXA at no cost

Available to those who need it

US residents who have no insurance coverage
and whose household income falls at or below 300%
of the US Federal Poverty Level are
eligible. Patients are
required to provide
income verification.

See application for additional terms and conditions

Simple to apply

Just complete and submit the
downloadable forms

Quick and direct

Upon determination of patient eligibility,
EUFLEXXA will be shipped to your office

Patient Assistance
Program Application

Download

HA=hyauronic acid.

Injection Support

Take a closer look at how
EUFLEXXA is administered

Deliver the full benefit of EUFLEXXA
with 3 injections over 3 weeks3

Watch the injection technique video

Injection Instructions

Download

HA=hyaluronic acid.

HAppy KNEES

A care management program
to help patients get the most
out of treatment

Keep your patients on track with the
information they need, when they need it

HAppy Knees infographic HAppy Knees infographic

Patients will receive a text to enroll after the first
benefits investigation
through the Solution
Center. For questions call 1-866-383-5391.

Learn what the HAppy Knees program
can do for you and your patients

The flexibility you need to help your patients get the treatment they need

* If your patient is enrolled through the Solution Center.

HA=hyaluronic acid; OA=osteoarthritis.

Commitment

The EUFLEXXA Commitment

Commitment ribbon If your patient is not satisfied with
their OA knee pain relief 10 weeks
after their last EUFLEXXA injection,
we offer up to a $100 refund for
copay costs. The patient must
have received 1 EUFLEXXA injection
a week x 3 weeks between
4/1/2019-12/31/2020.

Offer Terms and Conditions apply

To receive a refund, we need to receive the following from
your patient no later than 14 weeks after the last injection:

  1. Completed refund form
  2. Explanation of Benefits for each injection from the
    insurance company
  3. Receipts for their EUFLEXXA copay payment
  4. Fax the documents to 866-383-5392

Refund form

Download
The flexibility you need to help your patients get the treatment they need

HA=hyaluronic acid; OA=osteoarthritis.

Find out how to get EUFLEXXA for your patients today

Reference

  1. 1. Rolling 12 month average of IQVIA claims data based on unique patients (August 2018-August 2019). 2. Data on file. Ferring Pharmaceuticals Inc. 3. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.

    US-EU-2000115

Please see Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see FULL PRESCRIBING INFORMATION.

Please see Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see FULL PRESCRIBING INFORMATION.